Response to Comments: MolDX: Plasma-Based Genomic Profiling in Solid Tumors

This document is an administrative response to comments on the MolDX Plasma-Based Genomic Profiling in Solid Tumors LCD (DL38043/L38043) and records the public comment, notice, and effective dates. It does not itself define clinical coverage criteria, indications, limitations, documentation requirements for claims, or frequency limits.

"This document is a response to public comments on MolDX DL38043 (LCD L38043) and records the comment period (5/6/2019–6/20/2019), notice period start (12/19/2019), and effective date (2/3/2020)."

Sign up to see full coverage criteria, indications, and limitations.